Venus Aerospace has worked with NASA on testing its unique engine technology. Photo courtesy Venus Aerospace

A Houston-headquartered space tech company that's working on technology to enable hypersonic travel has announced a partnership with NASA to test its tech.

Venus Aerospace has partnered with NASA’s Marshall Space Flight Center in Huntsville, Alabama, on what is reportedly the longest sustained tests of a rotating detonation rocket engine, also known as an RDRE.

“Venus believes strongly in the performance step-change that RDREs bring for both hypersonic and space applications. The partnership with NASA has been key in maturing this new technology.” Andrew Duggleby, CTO and co-founder of Venus Aerospace, says in a news release.

The company's engine injector, which used regeneratively-cooled RDRE architecture, was tested in a "flight-like manner," according to the company. The technology operated successfully for 4 minutes of hotfire testing — a significant improvement, as engine tests of this type last for only 1 to 2 seconds, according to Venus.

"This long-duration hotfire means RDRE’s have retired a major risk area and are able to move into the few remaining steps before a flight demonstration," reads the press release from Venus.

As Venus continues to develop its technology for research, defense, and commercial missions, it will continue to work with NASA, which is also looking into RDRE technology for lunar and martian landers, in-space operations and logistics, and other deep space missions, per the release, because RDREs are more compact, efficient, and versatile than traditional rocket engines.

"Venus has entered into a second-year contract with NASA to provide engine parts for research and development of NASA’s RDRE," the news release continues. "In year two, NASA, with Venus’s support, will test different propellant combinations on hardware, to operate at even higher thrust levels and to demonstrate efficiency gains promised by the detonation engine."

Last summer, Venus added a new investor to its cap table. Andrew Duggleby founded Venus Aerospace with his wife and CEO Sarah "Sassie" Duggleby in 2020, before relocating to the Houston Spaceport in 2021. Last year, Venus raised a $20 million series A round.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”